BioLineRx Ltd.
A clinical-stage biopharmaceutical company developing therapies for oncology and rare diseases.
BLRX | TA
Overview
Corporate Details
- ISIN(s):
- US09071M2052 (+1 more)
- LEI:
- 529900AKIOSC15Y63R18
- Country:
- Israel
- Address:
- Modi'in Technology Park, 2 HaMa'ayan Street, 7177871 Modi'in
- Website:
- https://www.biolinerx.com/
- Sector:
- Manufacturing
Description
BioLineRx Ltd. is a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for oncology and rare diseases. The company leverages its drug development capabilities to advance novel, early-stage therapeutic candidates through the clinical development process toward regulatory approval. Its pipeline consists of treatments, including small molecules, designed to address unmet medical needs and deliver meaningful benefits to patients. BioLineRx also partners with other drug developers to advance their early-stage programs.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2025-11-24 15:01 |
Third Quarter 2025 Financial Results and Provides Corporate Update
|
English | 403.3 KB | ||
| 2025-11-24 15:01 |
Third Quarter 2025 Financial Results and Provides Corporate Update
|
English | 36.5 KB | ||
| 2025-11-17 15:01 |
BioLineRx Announces Receipt of USPTO Notice of Allowance for Key Patent Coverin…
|
Hebrew (modern) | 201.5 KB | ||
| 2025-11-17 15:01 |
BioLineRx Announces Receipt of USPTO Notice of Allowance for Key Patent Coverin…
|
English | 36.6 KB | ||
| 2025-09-29 16:02 |
BioLineRx Ltd. and Hemispherian AS Establish Joint Venture to Develop GLIX1, a …
|
English | 368.6 KB | ||
| 2025-09-29 16:02 |
BioLineRx Ltd. and Hemispherian AS Establish Joint Venture to Develop GLIX1, a …
|
English | 36.6 KB | ||
| 2025-08-14 16:01 |
Second Quarter 2025 Financial Results and Provides Corporate Update
|
English | 375.7 KB | ||
| 2025-08-14 16:01 |
Second Quarter 2025 Financial Results and Provides Corporate Update
|
English | 36.5 KB | ||
| 2025-07-26 23:19 |
Immediate Report
|
English | 397.4 KB | ||
| 2025-07-26 23:19 |
Immediate Report
|
English | 36.3 KB | ||
| 2025-07-01 01:25 |
Immediate Report
|
English | 127.3 KB | ||
| 2025-07-01 01:25 |
Immediate Report
|
English | 36.5 KB | ||
| 2025-05-30 17:23 |
New Pilot Phase Data from Phase 2 Combination Trial of Motixafortide in First-L…
|
English | 153.1 KB | ||
| 2025-05-30 17:23 |
New Pilot Phase Data from Phase 2 Combination Trial of Motixafortide in First-L…
|
English | 36.4 KB | ||
| 2025-05-27 16:01 |
BioLineRx Reports First Quarter 2025 Financial Results and Provides Corporate U…
|
English | 430.8 KB |
Automate Your Workflow. Get a real-time feed of all BioLineRx Ltd. filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for BioLineRx Ltd.
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for BioLineRx Ltd. via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
Peer Companies
